Kallyope | search
Click here to view Kallyope news from 60+ newspapers.
Bookmark or Share- Kallyope Raises $236M Series D Financing to Fuel Expansion of Novel Gut ...February 15th, 2022. Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the closing of a $236 million Series D financing co-led by Mubadala Investment Company and The Column Group, along with participation from other new and existing investors.
- Kallyope | Harnessing the Gut-Brain AxisOral, Small-Molecule Therapeutics. At Kallyope, we focus on big health challenges that matter to patients and families. We aim to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases. Scroll to learn more.
- Kallyope Pipeline | Novel TherapiesOur approach of directly targeting nutrient receptors in the gut through orally delivered molecules holds transformational potential to improve human health. We are currently advancing a diverse portfolio of novel, oral small-molecule therapies across three areas: metabolism, neurological disorders and gastrointestinal (GI) disease.
- Kallyope Enters Phase 2 With First-in-class Oral Approach for the ...Kallyope, Inc., a clinical stage biotechnology company discovering and developing novel, oral small-molecule therapeutics for diseases with high unmet need, today announced the initiation of their Phase 2 trial evaluating K-757 and K-833, new oral nutrient receptor agonists being studied for obesity and Type 2 diabetes.
- About Us | KallyopeWe aim to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases. Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of ...
More
